Clinical presentation, histopathology, and treatment outcomes of steroid-resistant nephrotic syndrome in children presenting in a tertiary care hospital in Pakistan

Mussarat Hussain; Sabeen Abid Khan; Muhammad Imran; Humaira Nasir

doi:10.32593/jstmu/Vol7.Iss2.289

Mussarat Hussain Department of Pediatrics, Shifa International Hospital, Islamabad, Pakistan
Sabeen Abid Khan Shifa College of Medicine, Shifa Tameer e Millat University, Islamabad, Pakistan
Muhammad Imran Shifa College of Medicine, Shifa Tameer e Millat University, Islamabad, Pakistan
Humaira Nasir Department of Pathology, Shifa International Hospital, Islamabad, Pakistan

DOI: https://doi.org/10.32593/jstmu/Vol7.Iss2.289

Keywords: Nephrotic Syndrome, Setroid-resistant, Children

Abstract

Introduction: Nephrotic syndrome (NS) is one of the most common glomerular diseases in children. Steroid-resistant nephrotic syndrome (SRNS), although represents a small fraction of NS is a challenging condition to manage. The study aims to review the clinical signs and symptoms, histopathology, and treatment outcomes of SRNS in children.

Methodology: This cross-sectional study was conducted in the Pediatric nephrology department of Shifa International Hospital from 1st September 2019 to February 2022. All children 1 to 18 years old fulfilling the criteria for SRNS patients were included. Their age of presentation, signs, symptoms, clinical findings, laboratory data, and histopathological findings on renal biopsy were noted. Outcomes like complete remission, partial remission, and chronic kidney disease were recorded.

Results: A total of 67 (25.8%) SRNS patients were included, mean age was 4.3 + 3.09 years. FSGS 21 (31.3%) was the most common, and MCD was seen in 9 (13.4%). Classic signs and symptoms of edema, weight gain, and abdominal distension were present in the majority. Oliguria, hematuria, and hypertension were significantly associated with a diagnosis of SRNS (p<0.05). In the laboratory workup, the mean albumin was 2.03 + 0.6 gm/l, the mean cholesterol 385.3 + 149 mg/dl, the mean serum creatinine was 2.1 + 1.16 mg/dl, and the mean protein creatinine ratio was 7.7 + 4.2. CKD and ESRD developed in 10 patients, and mortality was reported in 10 patients (P<0.005).

Conclusion: SRNS comprises a significant number of cases of NS resulting in ESRD with high morbidity and mortality.

Downloads

Download data is not yet available.

Author Biographies

Mussarat Hussain, Department of Pediatrics, Shifa International Hospital, Islamabad, Pakistan

Consultant Pediatric Nephrologist, Department of Pediatrics, Shifa International Hospital, Islamabad, Pakistan

Sabeen Abid Khan, Shifa College of Medicine, Shifa Tameer e Millat University, Islamabad, Pakistan

Associate Professor, Department of Pediatrics, Shifa College of Medicine, Shifa Tameer e Millat University, Islamabad, Pakistan

Muhammad Imran, Shifa College of Medicine, Shifa Tameer e Millat University, Islamabad, Pakistan

Senior Registrar, Department of Pediatrics, Shifa College of Medicine, Shifa Tameer e Millat University, Islamabad, Pakistan

Humaira Nasir, Department of Pathology, Shifa International Hospital, Islamabad, Pakistan

Consultant Histopathologist, Department of Pathology, Shifa International Hospital, Islamabad, Pakistan

References

Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018; 392(10141):61-74.

DOI: https://doi.org/10.1016/s0140-6736(18)30536-1

Dossier C, Lapidus N, Bayer F, Sellier-Leclerc AL, Boyer O, de Pontual L, et al. Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic? Pediatr Nephrol. 2016; 31(12):2299-2308.

DOI: https://doi.org/10.1007/s00467-016-3509-z

Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018; 392(10141):61-74.

DOI: https://doi.org/10.1016/S0140-6736(18)30536-1.

Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E, et al. Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol. 2009; 24:1525-32.

DOI: https://doi.org/10.1007/s00467-009-1138-5

Kemper MJ, Valentin L, Husen M. Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options. Pediatr Nephrol. 2018; 33:1641-9.

DOI: https://doi.org/10.1007/s00467-017-3780-7

Bensimhon AR, Williams AE, Gbadegesin RA. Treatment of steroid-resistant nephrotic syndrome in the genomic era. Pediatr Nephrol. 2019; 34(11):2279-2293.

DOI: https://doi.org/10.1007/s00467-018-4093-1

Cattran DC, Feehally J, Cook HT, Liu ZH, Fervenza FC, Mezzano SA, et al. Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012; 2(2):139-274.

DOI: https://doi.org/10.1038/kisup.2012.9

Kemper MJ, Valentin L, Husen M. Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options. Pediatr Nephrol. 2018; 33:1641-9.

DOI: https://doi.org/10.1007/s00467-017-3780-7

Gruppen MP, Bouts AH, Jansen-van der Weide MC, Merkus MP, Zurowska A, Maternik M, et al. A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. Kidney Int. 2018; 93(2):510-8.

DOI: https://doi.org/10.1016/j.kint.2017.08.011

Iijima K, Sako M, Kamei K,. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials. Pediatr Nephrol. 2018; 33:1449-55.

DOI: https://doi.org/10.1007/s00467-017-3746-9.

Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatric Nephrol. 2001; 16:27182.

DOI: https://doi.org/10.1007/s004670000523.

Hahn D, Hodson EM, Willis NS. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015; (3):Cd001533.

DOI: https://doi.org/10.1002/14651858.CD001533.pub5.

Trautmann A, Vivarelli M, Samuel S. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020; 35(8):1529-1561.

DOI: https://doi.org/10.1007/s00467-020-04519-1

Trautmann A, Schnaidt S, Lipska-Ziętkiewicz BS, et al. Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children. J Am Soc Nephrol. 2017; 28(10):3055-3065.

DOI: https://doi.org/10.1681/ASN.2016101121

Han KH, Kim SH. Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children. Biomed Res Int. 2016; 2016:3053706.

DOI: https://doi.org/10.1155/2016/3053706.

Zagury A, Oliveira AL, Montalvão JA. Steroid-resistant idiopathic nephrotic syndrome in children: long-term follow-up and risk factors for end-stage renal disease. J Bras Nefrol. 2013; 35(3):191-9.

DOI: 10.5935/0101-2800.20130031

Moorani KN, Hotchandani HM, Zubair AM. Immunosuppressive therapy in children with primary nephrotic syndrome: single center experience, Karachi, Pakistan. BMC Nephrol. 2019; 20(1):239.

DOI: https://doi.org/10.1186/s12882-019-1347-5.

Vivarelli M, Massella L, Ruggiero B. Minimal change disease. Clin J Am Soc Nephrol. 2016; 12(2):332-45.

DOI:https://doi.org/ 10.2215/CJN.05000516

Lee JM, Kronbichler A, Shin JI, Oh J. Current understandings in treating children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2021; 36(4):747-761.

DOI: https://doi.org/10.1007/s00467-020-04476-9

Kamei K, Ishikura K, Sako M, Ito S, Nozu K, Iijima K. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children. Pediatr Nephrol. 2020; 35:17-24.

DOI: https://doi.org/10.1007/s00467-018-4166-1.

Mason AE, Sen ES, Bierzynska A, Colby E, Afzal M, Dorval G, et al. Response to first course of intensified immunosuppression in genetically stratified steroid resistant nephrotic syndrome. Clin J Am Soc Nephrol. 2020; 15(7):983-94.

DOI: https://doi.org/10.2215/CJN.13371019